Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2021-04-15 Annual Report
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Vicore Pharma offentliggör årsredovisning för 2020
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2020' (Annual Report 2020) for Vicore Pharma Holding AB. It contains a comprehensive overview of the company's activities, financial statements (koncern and moderföretag), notes, board and management information, and an audit report (Revisionsberättelse). It is a full-length annual report, not an announcement or a summary, and thus fits the definition of a 10-K (Annual Report). FY 2020
2021-04-15 Swedish
Kallelse till årsstämma i Vicore Pharma Holding AB (publ)
AGM Information Classification · 99% confidence The document is titled "Kallelse till årsstämma i Vicore Pharma Holding AB (publ)" which translates to "Notice of Annual General Meeting in Vicore Pharma Holding AB (publ)". The text details the procedures for the AGM, including the fact that it will be held via advance voting (poströstning) due to COVID-19, the prerequisites for participation, the proposed agenda items (which cover board elections, auditor appointments, remuneration, and shareholder resolutions), and specific proposals related to remuneration guidelines (Ärende 14). This content is characteristic of a formal notice calling shareholders to the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2021-04-08 Swedish
Notice of annual general meeting of Vicore Pharma Holding AB (publ)
AGM Information Classification · 98% confidence The document is explicitly titled "Notice of annual general meeting of Vicore Pharma Holding AB (publ)" and details the procedures for holding the meeting via advance voting due to COVID-19. It outlines the agenda, which includes the election of the chairman, board members, auditors, and resolutions on remuneration and share issuance. This content is characteristic of the preparatory materials sent to shareholders before an Annual General Meeting (AGM). While it contains elements that might appear in a Proxy Statement (PSI), the primary focus is the formal notice and agenda for the AGM itself. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length (over 5,000 characters) confirms it is the full notice, not just a brief announcement (RPA).
2021-04-08 English
Ökning av antalet aktier och röster i Vicore Pharma
Share Issue/Capital Change Classification · 98% confidence The document is a short announcement dated March 31, 2021, detailing an increase in the number of outstanding shares and registered share capital for Vicore Pharma Holding AB (publ) following a directed new share issue approved by an extraordinary general meeting. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV).
2021-03-31 Swedish
Increase of number of shares and votes in Vicore Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces an 'Increase of number of shares and votes in Vicore Pharma' resulting from a directed share issue approved at an Extraordinary General Meeting. This action directly relates to changes in the company's capital structure (issuance of 11,200,000 new shares) and the resulting total number of outstanding shares and registered share capital. This aligns perfectly with the definition of 'Share Issue/Capital Change' (Code: SHA). It is not a general financing update (CAP) because it details a specific completed share issuance, nor is it a dividend announcement (DIV) or a transaction in own shares (POS, as this was an issuance to raise capital, not a buyback).
2021-03-31 English
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage by 'Handelsbanken Fonder AB' in 'Vicore Pharma Holding AB'. It explicitly shows the 'Before the transaction' and 'After the transaction' share quantities and resulting percentages, crossing a threshold (implied by the structure and the note about 'Flaggning' which means flagging/notification in Swedish context). This structure perfectly matches the definition of a Major Shareholding Notification, where an entity reports crossing a significant ownership threshold. The relevant code is MRQ.
2021-03-23 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.